Regeneron Pharmaceuticals Inc

REGNNASDAQ • USD
ThemeBiotech - Drug Development›Immunology & Autoimmune
741.07 USD
↗ 6.26 (0.85%)🟢PRE MARKET (AS OF 08:47 AM EDT)
🟢Market: OPEN

Regeneron Pharmaceuticals Inc (REGN) trades at $741.07 per share. The technical outlook is "Strong Sell" and the fundamental picture shows "Neutral". Key drivers include a robust Altman Z-Score and a bullish Golden Cross on the moving averages. REGN is fairly valued relative to its sector peers based on current multiples.

Technical & fundamental data as of Oct 1, 2026.

Open?$738.50
High?$741.07
Low?$733.57
Prev. Close?$734.81
Volume?927
Avg. Volume?723.9K
VWAP?$735.71
Rel. Volume?0.00x
Bid / Ask
Bid?$705.70 × 40
Ask?$775.21 × 40
Spread?$69.51
Midpoint?$740.46
Valuation & Ratios
Market Cap?75.7B
Shares Out?101.1M
Float?95.7M
Float %?94.6%
P/E Ratio?17.48
P/B Ratio?2.39
EPS?$42.04
Dividend?0.50%
Ex-Dividend?N/A
News
Profile
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
Themes
Biotech - Drug Development›Immunology & AutoimmuneHealthcare - Oncology›Immunotherapy & Immuno-OncologyHealthcare - Genomics & Precision Medicine›Gene Therapy & Gene Editing
Employees
15.4K
Market Cap
75.7B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.regeneron.com
Listed
1991-04-02
Address
777 OLD SAW MILL RIVER ROAD
TARRYTOWN, NY 10591
Phone: (914) 847-7000
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
60
Z-Score?
100
Momentum?
48
Short Sent.?
57
Piotroski F-Score?5/9Mixed
Altman Z-Score?6.84Safe
Confidence?69%Moderate
Full Fundamental Analysis →
Short InterestModerate
Short % of Float?2.64%Low
Short Interest?2.5M
Days to Cover?4.4
Free Float95.7M
Avg Daily Volume571.3K
Settlement Date2026-09-15
Financial Health
Current Ratio?3.34Strong
Quick Ratio?2.78Strong
Cash Ratio?0.44Low
Debt/Equity?0.09Low
ValuationFAIRLY VALUEDvs 10 peers + S&P 500
Score
78/100
P/E?
Peers
100
S&P
73
17.5CHEAP▾
P/B?
Peers
70
S&P
66
2.39CHEAP▾
P/S?
Peers
91
S&P
30
4.87FAIR▾
P/FCF?
Peers
75
S&P
55
20.1FAIR▾
EV/EBITDA?
Peers
75
S&P
36
17.4FAIR▾
EV/Sales?
Peers
91
S&P
37
4.89FAIR▾
Returns & Efficiency
ROE?
Peers
50
S&P
50
13.7%STRONG▾
ROA?
Peers
71
S&P
75
10.4%STRONG▾
Cash Flow & Enterprise
FCF?$3.8B
Enterprise Value?$75.9B
Fundamentals ratios updated end of day
MarketsMoversWatchlist